Skip to main content

Viracta Therapeutics, Inc. (VIRX)

NASDAQ: VIRX · IEX Real-Time Price · USD
6.12
+0.03 (0.49%)
After-hours:Oct 22, 2021 7:58 PM EDT
6.09
-0.02 (-0.33%)
At close: Oct 22, 4:00 PM
Market Cap227.45M
Revenue (ttm)n/a
Net Income (ttm)-97.85M
Shares Out37.22M
EPS (ttm)-6.21
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume170,595
Open6.13
Previous Close6.11
Day's Range5.95 - 6.28
52-Week Range3.92 - 24.80
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 15, 2021

About VIRX

Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. It is developing nanatinostat, an oral combination therapy in combination with the antiviral agent valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma. The company was founded in 2007 and is headquartered in Cardiff-by-the-Sea, California.

IndustryBiotechnology
Founded2007
CEODayton Misfeldt
Employees20
Stock ExchangeNASDAQ
Ticker SymbolVIRX
Full Company Profile

Financial Performance

In 2020, VIRX's revenue was $120,000, a decrease of -94.21% compared to the previous year's $2.07 million. Losses were -$21.61 million, -7.37% less than in 2019.

Financial Statements

News

Viracta Therapeutics Initiates Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors

SAN DIEGO, Oct. 6, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the initiation of a multinational...

2 weeks ago - PRNewsWire

Viracta Therapeutics to Present at Upcoming Investor Conferences in September

SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management will pre...

1 month ago - PRNewsWire

Viracta Therapeutics Reacquires Exclusive Development and Commercialization Rights for its All-Oral Combination Thera...

SAN DIEGO, Aug. 23, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has reacquired the exclu...

2 months ago - PRNewsWire

Viracta Therapeutics Announces the Appointment of Flavia Borellini, Ph.D., and Jane F.

SAN DIEGO, Aug. 16, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointments of Flavia Borel...

2 months ago - PRNewsWire

Viracta Therapeutics Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates

SAN DIEGO, Aug. 12, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc.  (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced financial results for the secon...

2 months ago - PRNewsWire

Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (...

SAN DIEGO, July 21, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Food and Drug Admi...

3 months ago - PRNewsWire

Viracta Therapeutics Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer and Key Additio...

SAN DIEGO, July 6, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Ayman El-Guind...

3 months ago - PRNewsWire

Viracta Therapeutics Announces its Addition to the Russell 2000® Index and other FTSE Russell Indexes

SAN DIEGO, June 28, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has been added as a memb...

3 months ago - PRNewsWire

Viracta Therapeutics Announces the Initiation of NAVAL-1, a Global Pivotal Trial for the Treatment of Relapsed/Refrac...

SAN DIEGO, June 1, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the initiation of NAVAL-1 (Nanati...

4 months ago - PRNewsWire

Viracta Therapeutics to Host Key Opinion Leader Webinar

SAN DIEGO, May 18, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX) (Viracta), a precision oncology company targeting virus-associated malignancies, will host a key opinion leader (KOL) we...

5 months ago - PRNewsWire

Viracta Therapeutics Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates

SAN DIEGO, May 12, 2021 /PRNewswire/ --  Viracta Therapeutics, Inc. (Nasdaq: VIRX) (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced financi...

5 months ago - PRNewsWire

Viracta Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

SAN DIEGO, April 8, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company managemen...

6 months ago - PRNewsWire

Why Sunesis, Poseida, Salarius And PRA Health Are Rallying

A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of Merger Deal: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), a biophar...

Other symbols:PSTXSLRX
8 months ago - Benzinga

SNSS Stock: Why Sunesis Pharmaceuticals Is Soaring Today

An analyst upgrade is the near-term catalyst, but for Sunesis Pharmaceuticals, it's really about patents in oncology and an impending merger with Viracta. The post SNSS Stock: Why Sunesis Pharmaceutical...

8 months ago - InvestorPlace

SUNESIS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sun...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Sunesis Pharmace...

9 months ago - Business Wire

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. - SNSS

NEW YORK, Dec. 4, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City...

10 months ago - PRNewsWire

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Sunesis Pharmaceuticals, Inc. Merger

WILMINGTON, Del., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Sunesis Pharmaceuticals, Inc. (“Sunesis”) (NASDAQ CM: SNSS) regarding possible breaches of f...

10 months ago - GlobeNewsWire

Implied Volatility Surging for Sunesis Pharmaceuticals (SNSS) Stock Options

Investors need to pay close attention to Sunesis Pharmaceuticals (SNSS) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

SHAREHOLDER ALERT: WeissLaw LLP Investigates Sunesis Pharmaceuticals, Inc.

NEW YORK, Nov. 30, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Sunesis Pharmaceuticals, Inc. ("Sunesis...

10 months ago - PRNewsWire

Sunesis Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Sunesis Pharmaceuti...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) and Viracta Therapeutics, Inc. is fair...

10 months ago - Business Wire

Sunesis Pharmaceuticals News: 7 Things for SNSS Stock Investors to Know About the Viracta Deal

Shares of SNSS stock are climbing higher on Monday after Sunesis Pharmaceuticals announced a merger deal with Viracta Therapeutics. The post Sunesis Pharmaceuticals News: 7 Things for SNSS Stock Investo...

10 months ago - InvestorPlace

Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement

Merger to c reate Nasdaq-listed company focused on developing Viracta's precision oncology pipeline targeting virus-associated malignancies

10 months ago - GlobeNewsWire

Sunesis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Recent Highlights

Sunesis to Host Conference Call Today at 4:30 PM Eastern Time Sunesis to Host Conference Call Today at 4:30 PM Eastern Time

11 months ago - GlobeNewsWire

Sunesis Pharmaceuticals to Host Conference Call on November 16th to Discuss Third Quarter 2020 Financial Results and ...

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Monday, November 16th, 2020 at 4:30pm E...

11 months ago - GlobeNewsWire

Sunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data at the 32nd EORTC-NCI-AACR Symposium on Mo...

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 32nd EORTC-NCI-AACR Symposium on Molecular Target...

1 year ago - GlobeNewsWire